000286718 001__ 286718
000286718 005__ 20240301121554.0
000286718 0247_ $$2doi$$a10.1093/clinchem/hvad180
000286718 0247_ $$2pmid$$apmid:38175594
000286718 0247_ $$2ISSN$$a0009-9147
000286718 0247_ $$2ISSN$$a1530-8561
000286718 0247_ $$2altmetric$$aaltmetric:158073962
000286718 037__ $$aDKFZ-2024-00058
000286718 041__ $$aEnglish
000286718 082__ $$a610
000286718 1001_ $$0P:(DE-He78)d62d536fb73eb7644201ddaac56cf68f$$aPouyiourou, Maria$$b0$$eFirst author$$udkfz
000286718 245__ $$aFrequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary.
000286718 260__ $$aOxford$$bOxford University Press$$c2024
000286718 3367_ $$2DRIVER$$aarticle
000286718 3367_ $$2DataCite$$aOutput Types/Journal article
000286718 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1704720275_2019
000286718 3367_ $$2BibTeX$$aARTICLE
000286718 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000286718 3367_ $$00$$2EndNote$$aJournal Article
000286718 500__ $$a#EA:A360#LA:A360#
000286718 520__ $$aCancer of unknown primary (CUP) is defined as a primary metastatic malignancy, in which the primary tumor remains elusive in spite of a comprehensive diagnostic workup. The frequency and prognostic value of circulating tumor cells (CTCs), which are considered to be the source of metastasis, has not yet been systematically evaluated in CUP.A total of 110 patients with a confirmed diagnosis of CUP according to the European Society for Medical Oncology (ESMO) guidelines, who presented to our clinic between July 2021 and May 2023, provided blood samples for CTC quantification using CellSearch methodology. CTC counts were correlated with demographic, clinical, and molecular data generated by comprehensive genomic profiling of tumor tissue.CTCs were detected in 26% of all patients at initial presentation to our department. The highest CTC frequency was observed among patients with unfavorable CUP (35.5%), while patients with single-site/oligometastatic CUP harbored the lowest CTC frequency (11.4%). No statistically significant association between CTC positivity and the number of affected organs (P = 0.478) or disease burden (P = 0.120) was found. High CTC levels (≥5 CTCs/7.5 mL; 12/95 analyzed patients) predicted for adverse overall survival compared to negative or low CTC counts (6-months overall survival rate 90% vs 32%, log-rank P < 0.001; HR 5.43; 95% CI 2.23-13.2). CTC dynamics were also prognostic for overall survival by landmark analysis (log-rank P < 0.001, HR 10.2, 95% CI 1.95-52.9).CTC frequency is a strong, independent predictor of survival in patients with CUP. CTC quantification provides a useful prognostic tool in the management of these patients.
000286718 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000286718 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000286718 650_2 $$2MeSH$$aHumans
000286718 650_2 $$2MeSH$$aNeoplastic Cells, Circulating
000286718 650_2 $$2MeSH$$aNeoplasms, Unknown Primary: diagnosis
000286718 650_2 $$2MeSH$$aPrognosis
000286718 650_2 $$2MeSH$$aCost of Illness
000286718 7001_ $$0P:(DE-He78)c741dc7f974390ad4310349f29aac40b$$aBochtler, Tilmann$$b1$$udkfz
000286718 7001_ $$aCoith, Cornelia$$b2
000286718 7001_ $$00000-0001-6862-0888$$aWikman, Harriet$$b3
000286718 7001_ $$0P:(DE-He78)a3903480c7232195efbd7b0f6f8564e8$$aKraft, Bianca$$b4$$udkfz
000286718 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b5$$udkfz
000286718 7001_ $$00000-0003-1001-103X$$aStenzinger, Albrecht$$b6
000286718 7001_ $$00000-0003-0028-5643$$aRiethdorf, Sabine$$b7
000286718 7001_ $$00000-0001-5736-2772$$aPantel, Klaus$$b8
000286718 7001_ $$0P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aKrämer, Alwin$$b9$$eLast author$$udkfz
000286718 773__ $$0PERI:(DE-600)1468161-4$$a10.1093/clinchem/hvad180$$gVol. 70, no. 1, p. 297 - 306$$n1$$p297 - 306$$tClinical chemistry$$v70$$x0009-9147$$y2024
000286718 909CO $$ooai:inrepo02.dkfz.de:286718$$pVDB
000286718 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CHEM : 2022$$d2023-10-21
000286718 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000286718 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000286718 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000286718 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000286718 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000286718 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000286718 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000286718 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000286718 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000286718 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN CHEM : 2022$$d2023-10-21
000286718 9141_ $$y2024
000286718 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d62d536fb73eb7644201ddaac56cf68f$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000286718 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c741dc7f974390ad4310349f29aac40b$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000286718 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a3903480c7232195efbd7b0f6f8564e8$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000286718 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000286718 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-0028-5643$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000286718 9101_ $$0I:(DE-588b)2036810-0$$60000-0001-5736-2772$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000286718 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000286718 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000286718 9202_ $$0I:(DE-He78)A360-20160331$$kA360$$lKKE Mol. Hämatologie/Onkologie$$x0
000286718 9200_ $$0I:(DE-He78)A360-20160331$$kA360$$lKKE Mol. Hämatologie/Onkologie$$x0
000286718 9201_ $$0I:(DE-He78)A360-20160331$$kA360$$lKKE Mol. Hämatologie/Onkologie$$x0
000286718 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000286718 980__ $$ajournal
000286718 980__ $$aVDB
000286718 980__ $$aI:(DE-He78)A360-20160331
000286718 980__ $$aI:(DE-He78)C060-20160331
000286718 980__ $$aUNRESTRICTED